•
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN), partners in the development of innovative oncology treatments, have jointly announced the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for their co-developed TROP-2-targeted antibody drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd). This application seeks…
•
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostic solutions provider, has formed a strategic partnership with the Society for Neuroscience and Neurology, Chinese Research Hospital Association (SNN/CRHA). This collaboration is aimed at conducting comprehensive research into the genetic underpinnings of optic nerve-related diseases, marking a significant step…
•
China’s Biotheus Inc. has entered into a definitive acquisition agreement with Germany-based BioNTech SE (NASDAQ: BNTX), marking a significant expansion of BioNTech’s operations in China. The deal underscores BioNTech’s commitment to enhancing its research and development capabilities and production capacity in the region. Deal Terms and FinancialsUnder the agreement, BioNTech…
•
China-based ophthalmology specialist, Arctic Vision, has entered into a strategic collaboration with Japan’s Santen Pharmaceutical (TYO: 4536) for the commercialization of ARVN001, an innovative triamcinolone acetonide suprachoroidal injectable suspension. This partnership marks a significant step in the expansion of ophthalmic treatments, with Santen securing exclusive commercialization rights in mainland China…
•
Pfizer Inc. (NYSE: PFE) is reportedly considering the sale of its hospital unit, Pfizer Hospital, in response to pressure from activist investor Starboard Value, as per information from Reuters. The move is part of the US pharmaceutical giant’s strategy to divest non-core assets and focus on its core businesses. Background…
•
US-based biopharmaceutical company FibroGen Inc. (NASDAQ: FGEN) has released its Q3 2024 financial report, showing revenues of USD 46.3 million for the quarter, a 15% year-on-year (YOY) increase. The net loss narrowed significantly to USD 17.1 million, compared to USD 63.6 million during the same period last year. As of…
•
UK-based pharmaceutical giant AstraZeneca Inc. (AZ, NASDAQ: AZN) has reported its financial performance for the Q3 2024 period, showing a robust 21% year-on-year (YOY) increase in total revenues to USD 13.565 billion at constant exchange rates. Product sales also saw a significant 20% growth to USD 12.947 billion. Business Unit…
•
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a China-based biotech company, has released its Q3 2024 financial results, achieving total operating revenue of USD 1.002 billion, marking a 28% year-on-year (YOY) increase. Product revenue within this total saw a substantial 67% YOY rise to USD 993 million. For the…
•
Germany-based Bayer AG (ETR: BAYN) has released its Q3 2024 financial results, reporting a 0.6% year-on-year (YOY) growth in constant currency terms to EUR 9.968 billion (USD 10.59 billion) in global group sales. This growth was driven by strong performances in the Pharmaceuticals and Consumer Healthcare segments, offsetting a decline…
•
China-based Sunshine Lake Pharma Co., Ltd., (HKG: 1558) a member of the HEC Group, has entered into a licensing agreement with UK-headquartered Apollo Therapeutics Group Limited for the development of APL-18881 (HEC88473). This strategic deal grants Apollo exclusive rights to develop and commercialize the drug outside of Greater China, while…
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced a renewed attempt to spin off its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd (Xuanzhu Biopharm), for an initial public offering (IPO) on the Hong Kong Stock Exchange. This follows an earlier aborted effort to list on Shanghai’s Sci-Tech Innovation Board (STAR)…
•
Germany-based pharmaceutical major Boehringer Ingelheim has announced the initiation of a long-term collaboration with the Mary Tyler Moore Vision Initiative (MTM Vision), marking the first time a pharmaceutical company has joined the MTM Vision Consortium. This partnership signifies a significant step in collaborative research aimed at addressing vision-related complications of…
•
US-based Johnson & Johnson MedTech (J&J, NYSE: JNJ) has announced that it has received an investigational device exemption (IDE) from the US Food and Drug Administration (FDA), allowing its OTTAVA robotic surgical system to commence clinical trials at various sites across the United States. This approval marks a significant step…
•
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its Q3 2024 financial report, showcasing robust growth and providing updates on recent product highlights and corporate developments. Revenue Growth and Product PerformanceDuring Q3, Zai Lab reported product net revenues of USD 101.8 million, a 46% year-on-year (YOY) increase…
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced its financial results for the third quarter of 2024, reporting a significant increase in revenue. The company generated USD 160 million in revenue for the three months ended September 30, 2024, marking a 67% year-on-year (YOY) increase. Revenue Breakdown and Key DriversCollaboration…
•
Canhelp Genomics, a Chinese company specializing in oncology-focused molecular diagnostics, has formed a strategic partnership with Mirxes Singapore. Together, they will utilize their combined technological and operational strengths to offer solid tumor origin identification testing services to medical practitioners and patients in Singapore, Malaysia, Thailand, Indonesia, and the Philippines. Collaboration…
•
US-based Vesalius Therapeutics has entered into a strategic agreement with UK pharmaceutical giant GSK plc (NYSE: GSK, LON: GSK) to discover and develop innovative treatments for Parkinson’s disease (PD) and another undisclosed neurodegenerative condition. The alliance leverages Vesalius’ platform to identify novel intervention points in PD and an additional neurodegenerative…
•
US-based Flare Therapeutics Inc., a clinical-stage biotech company specializing in cancer therapies through the use of transcription factors, has announced a strategic discovery collaboration agreement with Swiss pharmaceutical giant Roche (SWX: ROG). The partnership will utilize Flare Therapeutics’ expertise in proteomics and mass spectrometry, along with its proprietary library of…
•
New York-based Schrödinger, Inc. (NASDAQ: SDGR), a leading software provider in accelerating drug discovery, has announced a strategic research collaboration and license agreement with Novartis (NYSE: NVS). This partnership is aimed at advancing multiple development candidates into Novartis’s portfolio for further development. Additionally, the two companies have reached an expanded…
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its therapeutic bivalent mRNA vaccine, SYS6026. This vaccine is indicated for the treatment of precancerous lesions caused by human papillomavirus (HPV) types 16 or 18. Vaccine…